Anuh Pharma Limited is engaged in the business of manufacturing and selling bulk drugs and chemicals. The Company's products include active pharmaceutical ingredients and corticosteroids. Its active pharmaceutical ingredients include macrolides, anti-TB, anti-malarial, antibacterial, anti-hypertension, expectorant, quinolones, intermediates and under development. Its macrolides products include erythromycin, erythromycin ethyl succinate, erythromycin stearate, erythromycin estolate, erythromycin propionate, erythromycin phosphate, and others. Its anti-malarial products include sulfadoxine, pyrimethamine, and others. The Company's anti-hypertension products include losartan potassium, telmisartan and atorvastatin calcium. The Company's corticosteroids include anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, antihistamines and under development. Its anti-inflammatory products include dexamethasone Na phosphate, mometasone furoate and clobetasol butyrate.
ANUH PHARMA LIMITED Financial Highlights
- Revenue: ANUH PHARMA LIMITED reported revenue of ₹776.02 crore in FY26 vs ₹670.97 crore in FY25. It showed an increase of 15.66% on a yearly basis.
- Operating Profit: ANUH PHARMA LIMITED reported an operating profit of ₹54.22 crore in FY26 vs ₹61.01 crore in FY25. It showed a decrease of 11.13% on a year-on-year basis.
- Net Profit: ANUH PHARMA LIMITED reported a net profit of ₹41.05 crore in FY26 vs ₹47.35 crore in FY25. It showed a decrease of 13.31% on a yearly basis.
ANUH PHARMA LIMITED Quarterly Result Highlights
- ANUH PHARMA LIMITED reported revenue of ₹200.87 crore in Mar 2026, compared with ₹198.97 crore in Dec 2025, representing an increase of 0.95% on a quarter-on-quarter (QoQ) basis.
- ANUH PHARMA LIMITED reported an operating profit of ₹15.52 crore in Mar 2026, compared with ₹17.83 crore in Dec 2025, representing a decrease of 12.96% on a quarter-on-quarter (QoQ) basis.
- ANUH PHARMA LIMITED reported a profit of ₹11.68 crore in Mar 2026, compared with ₹13.45 crore in Dec 2025, reflecting a decrease of 13.16% on a QoQ basis.
- The earnings per share (EPS) of ANUH PHARMA LIMITED stood at ₹4.10 during Mar 2026.